Upstart GeneTx launches, going head to head with Ovid on rare Angelman syndrome
An Illinois nonprofit has launched a startup developing a drug to treat Angelman syndrome – the genetic condition that’s also being tackled by Jeremy Levin’s higher profile upstart Ovid Therapeutics $OVID.
Levin, who you might know as the former business development chief at Bristol-Myers, was also Teva’s CEO for a brief stint before jumping into the biotech startup business. Ovid, his latest venture, just closed a $75 million IPO last year with a drug to take on Angelman syndrome, a rare disease that affects the nervous system.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.